Luveltamab tazevibulin is under clinical development by Sutro Biopharma and currently in Phase III for Epithelial Ovarian Cancer. According to GlobalData, Phase III drugs for Epithelial Ovarian Cancer have a 34% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Luveltamab tazevibulin’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Luveltamab tazevibulin overview
STRO-002 is under development for the treatment of solid tumors, relapsed/refractory cancers like epithelial ovarian cancer, endometrial carcinoma, fallopian tube cancer, peritoneal cancer, non-small cell lung cancer, triple negative breast cancer, adenocarcinoma and relapsed/refractory rare pediatric acute myeloid leukemia (AML). It is administered through intravenous route. It is developed based on Xpress CF plus platform technology. The drug candidate is a potent and Sutro proprietary hemia-sterlin derivative warhead. It is a monoclonal antibody conjugate that acts by targeting folate receptor alpha (FolR alpha) and has a hemiasterlin payload which targets tubulin.
Sutro Biopharma overview
Sutro Biopharma is a clinical-stage oncology company that carries out the discovery and development of cancer therapeutics. The company provides antibody-drug conjugates (ADCs), bispecific antibodies, cytokine-based immune-oncology therapies and vaccines through its XpressCF and XpressCF+ platforms. The company’s product pipeline includes STRO-002 and luvelta targeting ovarian cancer, endometrial cancer, adenocarcinoma, non-small cell lung cancer and GLlS2 pediatric acute myeloid leukemia; and STRO-004 for solid tumors. It is also developing partner programs such as VAX-24 and VAX-31 for invasive pneumococcal disease; MK-1484 which treats metastatic solid tumors; and STRO-003 targeting solid tumor and hematological cancers. It works in collaboration with pharmaceutical and biotechnology companies such as Merck & Co. Inc. and Astellas Pharma Inc. Sutro Biopharma is headquartered in South San Francisco, California, the US.
For a complete picture of Luveltamab tazevibulin’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
